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In the accompanying paper a sensitive and specific enzymatic method is described for the measurement of formiminoglutamic acid (1) . In this paper data are presented on the application of this method for the assay of formiminoglutamic acid in the urine of a variety of patients.
Formiminoglutamic acid is an intermediate in histidine metabolism, and requires tetrahydrofolic acid for its further metabolism. Previous results (2) (3) (4) (5) have demonstrated that the urinary excretion of this compound is markedly increased in folic acid-deficient rats. Formiminoglutamic acid has also been reported (6, 7) in the urine of several patients receiving folic acid antagonists, although the techniques available for these studies were relatively cumbersome and inaccurate.
Using the enzymatic procedure for the assay of formiminoglutamic acid, we large quantities of formiminoglutamic acid were subjected to the alkaline hydrolysis procedure described in the accompanying paper (1) . In all instances there was a 95
to 100 per cent disappearance of the material reacting in the formiminoglutamic-acid test.
RESULTS Urinary excretion of formiminoglutamic acid in the nonleukemic children and adults varied from 0 to 0.51 micromole per hour ( Table I ).
The children with acute leukemia who had not received amethopterin for at least one week prior to the study excreted 0 to 1.18 micromoles of formiminoglutamic acid per hour (Table II) . The three children in this group who had never been given the drug excreted 0 to 0.03 micromole per hour. Sixteen patients receiving amethopterin excreted quantities of formiminoglutamic acid in excess of 1.27 micromoles per hour; the excretion exceeded 8 micromoles in 11 of these cases (Table III) . A rise in formiminoglutamic acid excretion was not apparent until after several weeks of amethopterin therapy, and often not until long after the patient had experienced a remission. Thus, Patient 33 excreted 0.59 micromole per hour 12 weeks following the institution of treatment, and 60 micromoles after 18 weeks; in Patients 26, 43 and 44 a similar phenomenon was observed. Following the cessation of therapy, Patients 34, 47 and 55 showed a sharp fall in formiminoglutamic acid excretion. The quantity of formiminoglutamic acid in the urine has no apparent relationship to the response of the leukemic process to therapy.
No evidence was found in any of the urines for any substances that would interfere with the formiminoglutamic acid assay. This was demonstrated by recovery experiments in which the urine samples were assayed after the addition of known increments of formiminoglutamic acid; 95 to 100 per cent recovery was obtained in all cases tested. 829 The increased excretion was often not seen until after several weeks or months of therapy. It should be noted that the quantity of amethopterin given was relatively small, so as to avoid toxicity. It is of considerable interest that in several patients a complete remission of the leukemia had taken place well in advance of an increase in formiminoglutamic acid excretion, or in formic acid excretion (9) . If the increase in urinary formiminoglutamic acid and formic acid can be considered an index of folic acid deficiency (2-5), these observations may provide in vivo support for the thesis that leukemic cells have a greatly increased sensitivity to folic acid deprivation (10).
SUMMARY
An enzymatic procedure has been applied to the assay of formiminoglutamic acid in the urine of adults and children with a variety of disease states. Urinary formiminoglutamic acid was fre- quently detected in small quantities, and was markedly increased in children treated with the folic acid antagonist, amethopterin.
